Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Pharma Sells Grand Island, N.Y. Plant to APP Pharmaceuticals In Consolidation Move

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Astellas Pharma said Sept. 5 it had sold its Grand Island, N.Y. plant that manufactures atopic dermatitis treatment Protopic (tacrolimus) to APP Pharmaceuticals of Schaumburg, Ill

You may also be interested in...



Astellas And Maxygen Ink Global Development Deal For Autoimmune Candidate MAXY-4

Maxygen's early-July decision to bear down on advancing its lead neutropenia compound and next-generation CTLA4-Ig drugs, letting Bayer take its hemophilia program, is paying off with Astellas, which signed a global deal that brings $10 million up front

Astellas And Maxygen Ink Global Development Deal For Autoimmune Candidate MAXY-4

Maxygen's early-July decision to bear down on advancing its lead neutropenia compound and next-generation CTLA4-Ig drugs, letting Bayer take its hemophilia program, is paying off with Astellas, which signed a global deal that brings $10 million up front

U.S. FDA Inspected “Wrong” Heparin API Manufacturer – Compliance Official

U.S. FDA failed to inspect a Chinese API manufacturer that may be linked to a recent heparin safety scare because the wrong Chinese firm was entered into an agency database, a compliance official said Feb. 18

Related Content

UsernamePublicRestriction

Register

PL007508

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel